10 July 2008: With reference to stock exchange notice of June 26, 2008, regarding subscription period and the prospectus related to the public offering. As previously communicated, NorDiag ASA has offered a minimum of 15,000,000 and a maximum 25,002,457 new shares at a subscription price of NOK 2 in a public offering with pre-emptive rights for the Company`s shareholders as per June 18, 2008.

After the close of the subscription period yesterday, July 9, 2008, a total of 15,113,744 shares has been subscribed for, of which approximately 1.36 million shares were subscribed for under the underwriting syndicate. Consequently, the share capital of NorDiag ASA will increase from NOK 3,832,381.50 to NOK 5,343,755.90, divided between a total of 53,437,559 outstanding shares with a nominal value of NOK 0.10. A letter with details on allotment will be sent to all subscribers on or about 15 July 2008.

The share issue, including payment and transfer of shares, is expected to be completed around July 29, 2008.

For more information, please contact:
CEO Mårten Wigstøl
Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections.

The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

For further information, please see www.nordiag.com
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Click here for information in Norwegian.